catamaran rx (now optumrx) (health trans)

Catamaran officially becoming OptumRx

Effective October 1, 2015, Catamaran, Caterpillar's pharmacy benefit manager (PBM), will change its name to OptumRx. This PBM branding change doesn't impact design or coverage under our prescription drug plan.

Plan participant materials mailed from Catamaran will start to show OptumRx branding. Catamaran ID cards will continue to be accepted at pharmacies and won't need to be replaced. The processing information and phone number listed on the cards are not changing.  

Nothing! It's a name change only. If you're a plan participant, you can continue to access your pharmacy records and drug information using the same website ( mycatamaranrx.com ) and mobile app (OptumRx/CatamaranRx in your mobile device's app store) as always. You may also access prescription drug benefit information at benefits.cat.com .

Cookie Policy

• AIDS Conference
• Asembia’s Specialty Pharmacy Summit
• Population Health Perspectives

• Conferences
• Publications

UnitedHealth Group acquires Catamaran for $12.8 billion

UnitedHealth Group’s announcement that its free-standing pharmacy care services business, OptumRx, will merge with Catamaran Corp., the fourth largest pharmacy benefit manager in the U.S., makes sense, according to industry experts.

UnitedHealth Group’s announcement that its free-standing pharmacy care services business, OptumRx, will merge with Catamaran Corp., the fourth largest pharmacy benefit manager (PBM) in the U.S., makes sense, according to industry experts.

UnitedHealth Group  plans to acquire  Catamaran for about $12.8 billion in cash, the Wall Street Journal reported.

“This is a smart acquisition well aligned with UnitedHealth’s strategy-increasing their market power, adding to their suite of technology and benefit management offerings, further diversifying their non-risk business, and better positioning them for the rapidly changing post-ACA delivery system and specialty pharmacy market,” says Kip Piper, MA, FACHE, advisor with Sellers Dorsey , a Medicaid consultancy in Washington, D.C.  “It will increase their already formidable leverage in pharma, biotech, and pharmacy price negotiations. UnitedHealth will no doubt take advantage of the wealth of data, IT savvy, and diverse client base Catamaran brings to the deal.”

This merger is consistent with the types of consolidation being seen within the industry, according to Robert Taketomo, PharmD, MBA, president and CEO, Ventegra .

“However, it remains to be seen in this particular case how the desired efficiencies from scale will impact the ability to adapt to a healthcare environment in flux, and how potential channel conflict with health plan clients will be addressed,” Taketomo says.

The agreement calls for the acquisition of Catamaran’s outstanding common stock for $61.50 per share in cash. The transaction is expected to close during the fourth quarter of 2015, subject to Catamaran shareholders’ approval, regulatory approvals and other customary closing conditions. The combination diversifies OptumRx’s customer and business mix, while accelerating its technology leadership and flexible service offerings.

NEXT: Purchase details

The acquisition is expected to be accretive to UnitedHealth Group’s net earnings in the area of $0.30 per share in 2016. UnitedHealth Group plans to finance the acquisition from existing cash resources and new debt. The company affirmed its $6.00 to $6.25 per share earnings outlook assuming the absorption of all merger costs, the ongoing commitment to advance its dividend policy as planned, and a continued but moderated level of share repurchase.

“It is generally acknowledged that most such takeovers result in a transfer of wealth or value from the acquirer's shareholders to the seller's shareholders. As such, it is a good deal for Catamaran,” says Mark O. Dietrich, CPA/ABV, cpa.net , a certified public accounting firm specializing in healthcare valuation, and author of “The Financial Professional's Guide to Healthcare Reform.” “Initial reaction in the market, however, was positive for United with its share price increasing, so perhaps this deal will be an exception.

“Pharmacy costs represent a significant portion of healthcare spending in the United States, reportedly rising 12% last year, and cost control is critical,” Dietrich adds. “The pharmacy chain CVS controls one large PBM, while its competitor Walgreens sold its PBM. At least from a standard view of economics, it would appear to make more sense to have PBMs under insurer control rather than the control of the industry they attempt to manage the costs of.”

This combination is expected to create a dynamic competitor in the PBM market by combining the strengths of Catamaran’s industry-leading technology platform with the data and analytics capabilities of Optum. The combined company is expected to deliver an innovative and compelling consumer and payer services offering that will link demographic, lab, pharmaceutical, behavioral and medical treatment data to engage individuals to make better decisions as they seek the best, most effective care and improve compliance with pharmaceutical use and care protocols.

Given the business imperatives of post-Affordable Care Act policy and market environment, super low cost of capital, large corporate cash reserves, the increasing power of data and technology, and intense pressures on pricing and cost efficiency, the industry can expect more M&A activity in many segments of healthcare, according to Piper. 

“The marketplace is ripe for further vertical and horizontal consolidations in the drug supply chain and beyond,” Piper says.

“Consolidation leads to fewer choices for the users of PBMs, which of course include managed care executives,” Dietrich says. “Pharmacy costs and formularies are one element of a managed care plan's product design and may contain features regarded as competing with other managed care plans. For plans presently using, for example, United's OptumRx, a competing plan may be using Catamaran. Now, both competing managed care plans would be serviced by the same PBM.”

NEXT: OptumRx's approach

OptumRx’s advanced Clinical Synchronization approach connects pharmacy and care management systems, processes and teams to create deeper insights for higher quality, more consistent and compliant patient outcomes and savings for individuals and plan sponsors. Synchronization presents the entire patient health profile, rather than discrete pieces of an individual’s profile – a distinctive and critically important capability given the growth in U.S. spending on specialty pharmaceuticals.

Catamaran offers retail pharmacy network management, mail service pharmacy, pharmacy claims management and patient-centric specialty pharmacy services to a broad client portfolio, including health plans and employers, as well as healthcare information technology solutions to the industry. In 2015 Catamaran expects to fulfill more than 400 million prescriptions which, combined with OptumRx’s roughly 600 million annual scripts, will enable the combined entity to be a competitive force in the PBM industry. Enhanced purchasing and administrative improvements from the combination are expected to drive substantial value, with the majority of savings expected to directly benefit clients and individuals through reduced costs for prescriptions and enhanced pharmaceutical services.

Both companies have distinctive, rapidly growing specialty pharmacy services businesses. The combined organization will help customers manage the complex costs and outcomes as this portion of the pharmaceutical market expands from an estimated $100 billion in revenues in 2014 to potentially $400 billion annually by 2020.

“With pharmaceutical costs rising rapidly and the increasing prevalence of expensive specialty drugs targeting rare conditions, pharmacy costs are likely to represent an increasing share of healthcare spending in the future,” Dietrich says. “The PBM companies that control access to millions of insureds will play a critical role in determining pricing and insurance premiums.”

Extending the Capabilities of the EHR Through Automation

Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.

Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?

Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.

Personalizing, Simplifying Value-Based Care Models to Reduce Costs, Improve Health Outcomes for Patients

Briana Contreras, an editor of Managed Healthcare Executive, spoke with Brian Adams, President and CEO of Tabula Rasa HealthCare, in this month's episode of Tuning In to the C-Suite podcast.

Change Healthcare Outage Prompts Switch in Pharmacy Claims Processing, Cranks Up Tensions Between Independent Pharmacies and PBMs

The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.

UnitedHealth Group Unplugs Change Healthcare Information Systems To Contain Cyberattack

The information systems of Change Healthcare, a recently acquired subsidiary of UnitedHealth Group, were disconnected on Wednesday.

2 Commerce Drive Cranbury, NJ 08512

609-716-7777

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Newsletters
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My watchlist
• Stock market
• Biden economy
• Personal finance
• Stocks: most active
• Stocks: gainers
• Stocks: losers
• Trending tickers
• World indices
• US Treasury bonds
• Top mutual funds
• Highest open interest
• Highest implied volatility
• Currency converter
• Basic materials
• Communication services
• Consumer cyclical
• Consumer defensive
• Financial services
• Industrials
• Real estate
• Mutual funds
• Credit cards
• Balance transfer cards
• Cash back cards
• Rewards cards
• Travel cards
• Online checking
• High-yield savings
• Money market
• Home equity loan
• Personal loans
• Student loans
• Options pit
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing

New on Yahoo

• Privacy Dashboard

UnitedHealth to buy pharmacy benefit firm Catamaran for $12.8 billion

By Sneha Banerjee (Reuters) - Health insurer UnitedHealth Group Inc agreed to buy Catamaran Corp in a deal worth about $12.8 billion to boost its pharmacy benefit business as it competes with bigger rivals such as Express Scripts Holdings Co . Pharmacy benefit managers (PBM) administer drug benefits for employers and health plans and run large mail order pharmacies, helping them get better prices from drugmakers. As employers look to cut prescription costs on expensive drugs, the deal with Catamaran will give UnitedHealth's pharmacy benefits unit, OptumRx, the scale to negotiate favorable prices from pharmacy companies. U.S. drug prices rose 12 percent in 2014 due to a new treatment for hepatitis C that cost more than $80,000 but cured almost all recipients with few side effects. Another new class of drugs, to treat high cholesterol, is expected to hit the market in 2015 and has insurers worried about drug costs this year as well. The purchase of Catamaran will increase UnitedHealth's market share to 15 percent to 20 percent of the people who receive their drug benefits through pharmacy benefit managers, BMO Capital Markets analyst Jennifer Lynch said in a research note. With a combined 1 billion scripts annually, UnitedHealth will be about the same size as current industry number two, CVS Health Corp , she added. Catamaran was formed after SXC Health Solutions and PBM Catalyst Health Solutions merged in 2012. UnitedHealth's offer of $61.50 per share represents a premium of 27 percent to Catamaran's Friday close on the Nasdaq. Catamaran's stock was trading at $60.01 premarket on Monday, while UnitedHealth was up nearly 4 percent. The deal "makes sense to us, but admittedly came much earlier than we expected," Jefferies analyst Brian Tanquilut said in a research note. "We had always viewed Catamaran as a compelling asset for companies looking for scale in the PBM sector such as Optum or Walgreens but expected Catamaran to grow the business much further before pursuing a sale." He added that the offer seemed adequate and he did not expect competing bids at this point. The deal value is based on Illinois-based Catamaran's total diluted shares outstanding as of Dec. 31. The transaction is expected to close in the fourth quarter of 2015 and add about 30 cents per share to UnitedHealth's profit in 2016, the companies said. Catamaran Chief Executive Officer Mark Thierer will be CEO of OptumRx and OptumRx CEO Timothy Wicks will become president. (Additional reporting by Caroline Humer in New York; Editing by Savio D'Souza, Saumyadeb Chakrabarty and Meredith Mazzilli)

Recommended Stories

Panic meter: drake london, marvin harrison jr., mark andrews + waiver wire pickups | yahoo fantasy forecast.

Week 1 is in the books and oh my there's a lot of panic on these fantasy streets. Dalton Del Don joins Matt Harmon for the regular season debut of 'People's Panic Meter' to answer all of your listener submissions. The duo examines the situations for Drake London, Marvin Harrison Jr., Dalton Kincaid, Mark Andrews and many more.

College Football Playoff Picture: Here's what the 12-team bracket looks like after Week 2

The first iteration of the 12-team College Football Playoff is only months away. After two weeks of action, the field is filled with SEC teams.

What credit card users need to know if the Fed cuts rates in September

The Fed may soon cut interest rates. Here’s why you should take control of your credit card debt now.

Mortgage and refinance rates today, September 10, 2024: 30-year rates finally under 5.75%

These are today's mortgage and refinance rates. Rates are down overall, and 30-year and 15-year fixed rates have reached new milestones. Lock in your rate today.

Asked & Answered: Steelers, Bengals have QB questions; Kyler Murray, Minnesota offer answers

Do the Steelers turn to Justin Fields or Russell Wilson? And is Joe Burrow's wrist cause for concern?

The Morning After: Should you upgrade to an iPhone 16?

The biggest news stories this morning: Everything Apple revealed at the iPhone 16 launch event, Google Pixel Watch 3 review, It looks like Sony will announce the PS5 Pro later today.

Nvidia stock sell-off is overdone, Goldman Sachs analyst says

Nvidia's sell-off is overblown, according to a semiconductor analyst with Goldman Sachs.

Deion Sanders wonders why Travis Hunter and Shedeur Sanders didn't get more Week 1 recognition

Colorado beat FCS school North Dakota State 31-26 in Week 1.

Apple Watch Series 10 hands-on: Bigger, lighter and thinner than ever

Our first up-close look at the new Apple Watch.

Apple reveals revamped AirPods lineup

Apple on Monday announced major updates to its popular AirPods line of earbuds.

Angels' Ben Joyce comes 0.3 mph short of fastest pitch ever recorded

The Angels flamethrower struck out the Dodgers' Tommy Edman with some ridiculous heat.

Deshaun Watson reportedly facing new sexual assault lawsuit dating back to 2020 with Texans; NFL launches review

Deshaun Watson was suspended by the league for 11 games in 2022 after he was accused by more than 20 women of sexual misconduct.

Matt LaFleur: Malik Willis will start as Packers QB if Jordan Love can't play, Love not ruled out for Week 2

Love was reportedly initially expected to miss 3-6 weeks with the MCL sprain he suffered in Week 1.

Saquon Barkley has monster debut as Eagles beat Packers in Brazil

The Eagles got a big win to start the season.

Apple iPhone 16 Pro vs. the competition: Bigger, with more buttons

We've broken down how the new Apple iPhone 16 Pro compares to the Google Pixel 9 Pro and Samsung Galaxy S24+, two other popular phones in the $1,000 range, on the spec sheet.

Week 2 Overreaction: Marcus Freeman is officially on the hot seat & Texas is a serious contender

Does every team in college football stink? Dan Wetzel, Ross Dellenger and SI's Pat Forde react to a wild Week 2 slate that featured many teams underperforming.

The AI supercycle is just beginning: AMD CEO

AMD CEO Lisa Su sets the table for a host of new AI chip rollouts.

Bad news for EVs: Consumers less likely to buy one compared to last year

In another blow to America’s EV transition, buyers are balking at purchasing a new EV.

Baseball Hall of Famer Wade Boggs announces prostate cancer diagnosis

Boggs played 18 seasons in MLB with the Red Sox, Yankees and Rays.

Apple needs to remember what the iPhone 16 is for

Apple needs to remember the iPhone shouldn't be used for everything.

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds Rates
• Top Mutual Funds
• Options: Highest Open Interest
• Options: Highest Implied Volatility
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Stock Comparison
• Advanced Chart
• Currency Converter
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Credit Card Offers
• Best Free Checking
• Student Loans
• Personal Loans
• Car insurance
• Mortgage Refinancing
• Mortgage Calculator
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Financial Freestyle
• Capitol Gains
• Living Not So Fabulously
• Decoding Retirement
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Unitedhealth to buy pharmacy benefit firm catamaran for $12.8 billion.

By Sneha Banerjee

(Reuters) - Health insurer UnitedHealth Group Inc (UNH.N) agreed to buy Catamaran Corp (CTRX.O)(CCT.TO) in a deal worth about $12.8 billion to boost its pharmacy benefit business as it competes with bigger rivals such as Express Scripts Holdings Co (ESRX.O).

Pharmacy benefit managers (PBM) administer drug benefits for employers and health plans and run large mail order pharmacies, helping them get better prices from drugmakers.

As employers look to cut prescription costs on expensive drugs, the deal with Catamaran will give UnitedHealth's pharmacy benefits unit, OptumRx, the scale to negotiate favorable prices from pharmacy companies.

U.S. drug prices rose 12 percent in 2014 due to a new treatment for hepatitis C that cost more than $80,000 but cured almost all recipients with few side effects. Another new class of drugs, to treat high cholesterol, is expected to hit the market in 2015 and has insurers worried about drug costs this year as well.

The purchase of Catamaran will increase UnitedHealth's market share to 15 percent to 20 percent of the people who receive their drug benefits through pharmacy benefit managers, BMO Capital Markets analyst Jennifer Lynch said in a research note.

With a combined 1 billion scripts annually, UnitedHealth will be about the same size as current industry number two, CVS Health Corp (CVS.N), she added.

Catamaran was formed after SXC Health Solutions and PBM Catalyst Health Solutions merged in 2012.

UnitedHealth's offer of $61.50 per share represents a premium of 27 percent to Catamaran's Friday close on the Nasdaq.

Catamaran's stock was trading at $60.01 premarket on Monday, while UnitedHealth was up nearly 4 percent.

The deal "makes sense to us, but admittedly came much earlier than we expected," Jefferies analyst Brian Tanquilut said in a research note.

"We had always viewed Catamaran as a compelling asset for companies looking for scale in the PBM sector such as Optum or Walgreens but expected Catamaran to grow the business much further before pursuing a sale."

He added that the offer seemed adequate and he did not expect competing bids at this point.

The deal value is based on Illinois-based Catamaran's total diluted shares outstanding as of Dec. 31.

The transaction is expected to close in the fourth quarter of 2015 and add about 30 cents per share to UnitedHealth's profit in 2016, the companies said.

Catamaran Chief Executive Officer Mark Thierer will be CEO of OptumRx and OptumRx CEO Timothy Wicks will become president.

(Additional reporting by Caroline Humer in New York; Editing by Savio D'Souza, Saumyadeb Chakrabarty and Meredith Mazzilli)

• Share full article

Advertisement

Supported by

UnitedHealth Group to Buy Catamaran in $12.8 Billion Pharmacy Benefits Deal

By David Gelles

• March 30, 2015

Two pharmacy benefits managers are combining forces in an effort to negotiate better deals with pharmaceutical makers, a move that could in theory lead to lower drug prices for consumers.

A unit of the UnitedHealth Group said it had agreed to acquire the Catamaran Corporation in an all-cash deal worth nearly $13 billion, the companies announced on Monday.

UnitedHealth will pay $61.50 a share for Catamaran, a 27 percent premium over Friday’s closing price of $48.32 a share. It is the latest big acquisition in the health care industry, which is in the midst of a surge of deal activity. And it represents a further consolidation of the pharmacy benefits management business.

Last month, Rite Aid, a big pharmacy chain, acquired Envision Pharmaceutical Services , for $2 billion in cash and stock.

Catamaran, which is based in Schaumburg, Ill., will be combined with UnitedHealth’s pharmacy services business, OptumRx. Catamaran manages more than 400 million prescriptions each year on behalf of 35 million people — or about one in every five prescription claims in the United States.

The combined company will face off against other big pharmacy benefits managers, including Express Scripts and CVS Caremark.

“We believe this combination will create significant value for health plan, government, third-party administrator and employer customers and, most importantly, the individual consumers who depend on us for accurate, affordable and convenient pharmacy benefit products and services,” Larry Renfro, chief executive of Optum, said in a statement.

UnitedHealth said the deal would add 30 cents a share to its net earnings in 2016. UnitedHealth plans to finance the acquisition from existing cash resources and new debt.

The deal is subject to approval by Catamaran’s shareholders and regulators, who may take a close look at an increasingly concentrated industry.

But even as it consolidates, the business is growing, too. Managing pharmacy benefits is expected to quadruple to a $400 billion market in 2020, up from $100 billion last year.

Mark Thierer, Catamaran’s chairman and chief executive, will become chief executive of OptumRx, while Timothy Wicks, the current chief executive of OptumRx, will become president.

“Our board of directors carefully considered a variety of strategic options and unanimously concluded that this combination is clearly in the best interests of our shareholders,” Mr. Thierer said. “Together, we believe we will have the talent, scale, technology resources and innovative spirit.”

Explore Our Business and Tech Coverage

Dive deeper into the people, issues and trends shaping the worlds of business and technology..

N.B.A. Podcast Co-hosts : For the friends of some famous athletes, hosting a show can mean a little money, some fame and a whole lot of work .

Self-Driving Cars: In places like San Francisco, Phoenix and Las Vegas, robot taxis are navigating city streets, each without a driver behind the steering wheel. But some get guidance from command centers  located hundreds of miles away.

OpenAI’s Chaotic Past: The maker of ChatGPT is struggling to transform itself into a profit-driven company  while satisfying worries about the safety of A.I.

Has Tipping Reached Its Limit?: Americans are being asked to tip more often and in more places than ever before. It may soon get worse .

The Coffee Wars: From Starbucks to specialty cafes, there is something of an arms race going on in the coffee world , as competitors battle to create the craziest, calorie-laden, not-really-coffee drink.

UnitedHealth Group to acquire Catamaran in a $12.8 billion deal

Health insurer UnitedHealth Group Inc. has announced that it has reached an agreement to purchase Catamaran Corp in a deal worth about $12.8 billion to promote its pharmacy benefit management, as it competes with bigger rivals such as Express Scripts Holdings Co.

As part of the deal, Catamaran, the fourth largest pharmacy benefit manager in the U.S., will be integrated into UnitedHealth Group’s OptumRx unit, the industry’s third-largest player and part of the Optum health-services arm of the health-care giant.

Pharmacy-benefit management companies like Catamaran administer drug benefits, working with employers and insurers to negotiate prescription drugs at a lower rate from pharmaceutical groups and pharmacists. They also maintain a patients list of covered drugs, handle mail orders or complex treatments and often oversee patients’ drug use.

As employers seek to reduce prescription costs on high price drugs, the deal with Catamaran will give UnitedHealth’s pharmacy benefits unit, OptumRx, the scale to arbitrate fair prices from pharmacy companies.

In 2014, U.S. drug prices surged 12 percent as a result of a new treatment for hepatitis C that cost more than $80,000 but cured almost all beneficiaries with few side effects. Another new class of drugs, to cure high cholesterol, is expected to be launched in 2015 and has insurers worried about drug costs this year as well.

On Monday, UnitedHealth offered to pay $61.50 per share of Catamaran, a 27% premium over Friday’s closing price of $48.32. UnitedHealth plans to fund the deal from existing cash reserves and new debt. The all-cash deal, which is subject to Catamaran shareholders’ approval is expected to close during the fourth quarter of 2015.

Schaumburg, Ill.-based Catamaran’s stock price surged 24 percent on Monday, while Minnetonka, Minn, based UnitedHealth Group’s shares rose by more than 2 percent.

The deal could even force other health mergers and acquisitions between Express Scripts the country’s largest PBM, and Walgreens Boots Alliance, the nation’s largest drugstore chain.

CVS also owns one of the nation’s biggest pharmacy chains, while Envision RX, a small pharmacy benefit manager, recently announced plans to be acquired by national drug store chain Rite Aid.

Pharmacy companies are able to use scale to negotiate reasonable prices. Previously, Express Scripts was able to procure a huge discount for a crucial hepatitis C drug from AbbVie Inc., and has said it will use its size to gain discounts for cholesterol drugs and cancer drugs in the future.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Popular Posts

RELATED POSTS

Apple iPhone 16 Launch: Models, Features, Price, Colors and More

Boeing's Tentative Labor Deal: 25% Wage Increase to Avoid Strike

99 Speed Mart Raises $542.8M in Landmark IPO, Stock Rallies on Debut

From Classroom to Boardroom: Success Stories of Young Entrepreneurs

Broadcom Stock Dips Nearly 5% After Weak Revenue and Merger Costs

Salesforce Expands Cloud Data Security with $1.9B acquisition of Own Co.

• Aerospace & Defense
• Financial Services
• Food & Services
• Healthcare & Pharmaceutical
• Logistics & Supply Chain
• Professional Services
• Media & Entertainment
• Manufacturing & Retail
• Emerging Markets
• Market Analysis
• New Ventures
• CEO Magazine
• Philanthropy
• Power Players
• Success Story
• Sustainability
• Communication
• Decision Making
• Productivity
• Strategic Thinking
• Work-Life Balance
• Executive Interviews
• Awards and Rankings
• Current Issue
• Past Issues

Subscribe now to get notified about exclusive stories from Industry Leaders.

UnitedHealth buys pharmacy-benefit manager Catamaran for $12.8B

UnitedHealth beefs up drug benefits role with Catamaran acquisition.

By Joe Carlson

The nation's largest health insurer, Minnetonka's United­Health Group Inc., will have more clout to push back against high drug prices with a $12.8 billion merger announced Monday.

UnitedHealth is acquiring Schaumberg, Ill.-based Catamaran Corp. in a move to gain control over how more than 1 billion prescriptions per year are dispensed. UnitedHealth's OptumRx unit was already the third-largest player in the nearly $300 billion business of managing prescription-drug benefits for Americans.

"It's a good thing for the consumer," said Leerink Partners health care analyst Ana Gupte. "We've had a lot of [drug] price issues, even beyond the wave of specialty drugs. Even within the existing brandeds and generics, the unit-price increases have been fairly significant."

Analysts and investors cheered the merger news because drug costs are a large and growing share of overall health care spending. Huge pharmacy-benefit management companies have fought against sky-high drug prices, and that battle is likely to become much more intense with the launch of a new generation of cancer drugs carrying six-figure price tags.

Pharmacy benefit managers, known in the industry as PBMs, are in the business of managing the pharmaceutical side of an insurance plan, including deciding which drugs are covered and what pharmacies or mail-order services beneficiaries use to get them. The companies can also be a potent force to negotiate bulk discounts on drugs, as was evident last year with pressure to lower costs for a $90,000 hepatitis C medication.

The PBM industry has risen rapidly since the creation of Medicare's prescription drug benefit in 2003, and now handles the management of about 4.4 billion prescriptions annually. But the industry has seen rapid corporate consolidation, especially following passage of the Affordable Care Act.

"We view the transaction as a positive for [UnitedHealth] as it cements Optum's position as a top player" in the PBM industry, Wells Fargo senior analyst Peter Costa wrote in a note to investors Monday.

By adding No. 4 player Catamaran, UnitedHealth's OptumRx will control 23 percent of the market, up from 14 percent. That puts it on par with the industry's biggest player, Express Scripts, which controls 30 percent of the market, and CVS/caremark's 25 percent share, according to Deutsche Bank analysts. The next-biggest company has 8 percent.

IBISWorld, which studies the industry, estimates that the $287 billion PBM market is on pace for 4.3 percent annual growth through 2020. "Growth prospects for PBMs are strong," the firm's report on the industry earlier this month said. "The 2010 Patient Protection and Affordable Care Act will expand prescription drug coverage over the next five years, which will help bolster prescription drug use and industry revenue as a result."

Investors approve

UnitedHealth on Monday agreed to pay Catamaran shareholders $61.50 per share, a 27 percent premium over Friday's closing price. The deal is expected to add 30 cents per share to UnitedHealth's earnings in 2016, following an expected closing at the end of 2015, pending shareholder and regulatory approvals.

Investors applauded the deal, sending shares of both companies higher. Catamaran stock jumped 24 percent on the news, and UnitedHealth Group gained 2.5 percent, closing at $121.

OptumRx had revenue of about $32 billion last year, while Catamaran had revenue of $21.6 billion.

UnitedHealth executives declined an interview request, but Optum's chief executive Larry Renfro said in a statement that the combination of the two companies would create "a unique offering in the industry unparalleled by current participants."

UnitedHealth Group is principally known for being the nation's largest health insurer, and its OptumRx business differentiates itself in the market by being able to inform its decisionmaking by analyzing claims on 114 million commercial and Medicare-covered beneficiaries. Catamaran, meanwhile, is known for its advanced technology platforms.

The combination is expected to allow company analysts to study patients' demographic, lab, pharmaceutical, behavioral and medical treatment data in new ways to improve medical decisionmaking and let patients better follow doctors' orders, the companies said in a statement.

Possible fallout

Stock analysts said the deal gives OptumRx a welcome ability to broaden its base beyond UnitedHealth Group customers. But it wasn't clear whether a good-sized chunk of Catamaran's business would flee with the deal. Health insurer Cigna is one of Catamaran's larger customers, but its managed-care business competes with UnitedHealth.

Costa's analysis noted that Cigna may try to pull out of its Catamaran deal, although Leerink's Gupta had a different take after talking with Cigna officials.

"They don't seem to show any concern or any interest in cleaving from Catamaran as a result of this," she said. "As long as they can share in some of the better economics from scale, they would be happy to stay with them."

Mark Thierer, Catamaran's chairman and chief executive, will become CEO of the combined OptumRx and Catamaran. Timothy Wicks, the current chief executive of OptumRx, will become president.

UnitedHealth Group is the state's largest publicly traded corporation by revenue. It reported revenue of $130.5 billion in 2014. In 2013, its revenue exceeded that of Target and Best Buy combined, according to the most recent Star Tribune 100 analysis of the state's top companies.

Joe Carlson • 612-673-4779

Twitter: @_JoeCarlson

about the writer

Joe carlson.

Joe Carlson writes about medical technology in Minnesota for the Star Tribune.

More from Business

Vista outdoor postpones sale vote, yet again, after new bid from mnc capital.

Anoka-based Vista Outdoor said Tuesday it would reschedule Friday’s shareholder meeting on the sale of its ammunition business to a Czech company after getting another bid from MNC.

Where did all these Target workers come from? Annual meeting brings influx to downtown Minneapolis

Target employees have flooded Minneapolis, bringing traffic for downtown businesses.

Essentia Health to drop from Medicare Advantage networks at UnitedHealthcare, Humana

Duluth-based health system cited high rates of claim denials and delayed payments as the reason for exiting the plans.

Storage Preferences

• Personalization
• Digital Editions

• Publications
• Brand Insights
• Conferences

OptumRx-Catamaran merger brings further consolidation to US pharma market

$12.8-billion acquisition will bring 1 billion precriptions/year under one PBM's management

Drugs are prescribed by physicians, but increasingly, the price and availability of those drugs are dictated by the pharmacy benefit managers (PBMs). With the proposed acquisition of Catamaran (Schaumburg, IL) by OptumRx, the PBM arm of United Health (New York), the number three PBM (OptumRx) solidifies its position by buying the No. 4 PBM. There had been a trend in recent years of health insurers unloading their PBM businesses (one of Catamaran’s main clients—at least for now—is health insurer Cigna); the OptumRx acquisition, to a degree, reverses that trend. Simultaneously, more of the chain-drugstore channel is hooking up with PBMs; witness last month’s announced acquisition of EnvisionRx by Rite Aid.

The top three PBMs represent exactly two-thirds of the prescription market, and the top seven (now six) represent 92%, according to data on “equivalent prescriptions dispensed” collected by Adam Fein at DrugChannels.net :

• Express Scripts
• CVS/Caremark

The OptumRx-Catamaran announcement noted that one of the drivers for the acquisition is that “Enhanced purchasing and administrative improvements from the combination are expected to drive substantial value, with the majority of savings expected to directly benefit clients and individuals through reduced costs for prescriptions and enhanced pharmaceutical services.”

One element of the PBM-pharma relationship is that several PBMs, including market leader Express Scripts (through its CuraScript distribution business) and Optum (a sister company of OptumRx) provide consulting and drug-development services to pharma. Optum’s website notes that it “supports “hundreds of life sciences companies as they research and develop new treatments.” The ability to quantify clinical outcomes, and to obtain patients for clinical trials, increasingly derives from data generated by PBMs’ and their payer-clients’ investments in healthcare data systems. Such “coopetition” is not unique; the Big Three drug wholesalers all have divisions that provide fee-based services to manufacturers, even as they haggle over the pricing of drugs they purchase. How pharma business managers operate in this ever-more constrained market is the big issue.

The Capabilities of a 3PL Provider

Chris Williams expands on the services that a third-party logistics (3PL) partner should offer, while sharing ways to alleviate standard supply chain issues.

Elevate Your Commercial Operations with Close-up CRM

Discover a powerful, cost-effective, and robust CRM platform that maximizes your budget. Seamlessly integrate data from any source, streamline marketing efforts, and optimize HCP promotion, key account management, and digital marketing campaigns. Reduce CRM costs and reallocate funds to enhance data analytics, market research, and human capital, boosting overall commercial operations impact.

Addressing the Drug Shortage Crisis

Peter Ax provides insight as to industry’s lack of supply, along with how to mitigate these issues.

AI-Enabled Pharma CRM Driving Intelligent Customer Engagement

Discover our unparalleled CRM solution that integrates AI/ML for enhanced stability, security, and performance. Leverage our team of 1000+ experts and 25K+ data provider partners. Our cloud-based SaaS model allows rapid global deployment and scalability, while our clean UX focuses on intuitive AI experience and rapid user adoption. Ensure swift 80% physician onboarding with our intuitive AI platform, speeding strategic integration.

Background of Close-Up

485 Route 1 South, Building F, Suite 210 Iselin, NJ 08830

732-596-0276

The Government has a fund to help COVID-19 victims’ families. Click here for more information.

OptumRx and Catamaran Are Latest Players to Consolidate in the PBM Market – How Will Your Pharmacy Be Affected?

UnitedHealth announced an agreement to acquire Catamaran for about $12.8 billion in cash, and is planning to merge the pharmacy benefit manager into its own, free-standing pharmacy benefits business, OptumRx. This deal is expected to close in the fourth quarter of 2015, after shareholder approval, regulatory approval and other customary closing conditions.

This deal is expected to combine the strength of Catamaran’s 400 million prescriptions with OptumRx’s 600 million annual prescriptions to rival the larger players like CVS/Caremark and Express Scripts. The merger is also expected to combine Catamaran’s technology platform with the data and analytics capabilities of OptumRx.

This merger has certain similarities to the Express Scripts and Medco $29.1 billion merger in 2012. This deal created one company filling a combined 1.4 billion prescriptions per year, and Express Scripts used Medco’s technology platform as well. At the time of the deal, Express Scripts and Medco were the largest and third-largest pharmacy benefits managers, respectively. The deal was scrutinized for eight months by the FTC for potential antitrust implications after being approved. However, the effect for pharmacies was that Express Scripts and Medco maintained separate contracts and networks for at least 18 months post-merger.

For specialty and compounding pharmacies, this may mean that the combined PBM may push for decreased reimbursements and may seek to force more patients through mandatory, in-house mail order and specialty pharmacies. In addition, programs initiated and implemented by Catamaran may not carry forward to the merged entity.

Value Based Care insights

Defending the Inventory Shortfall: More Complex than First Appears On-Demand Webinar Replay September 17, 2021

Considerations for Manufacturers When Structuring Value-Based Agreements and Value-Based Pricing February 22, 2023

Value Based Care | Articles

Rise West 2024 September 11, 2024

Let us help you find solutions .

Subject Healthcare Law Pharmacy Law How did you hear about us? Webinar Article Referral Source LinkedIn Twitter Instagram Google Word of Mouth

Please leave this field empty.

• Our Attorneys
• Administrative and Insurance Defense Law
• Advocacy and Government Affairs
• Ambulatory Care Facility Formation & Representation
• Change of Ownership (CHOW)
• Clinical Trials / Human Subjects Research
• Data Transactions
• Drug and Device Advertising, Marketing & Promotion Legal Review
• Employment Matters
• Federal and State Fraud and Abuse Counseling
• Healthcare Litigation
• Healthcare Practice Compliance
• HIPAA Compliance
• Hospital/Physician Negotiations and Joint Ventures
• In-house Counsel Legal Support Services
• Intellectual Property Services
• Managed Care Negotiations and Strategies
• Medical Practice Mergers & Supergroups
• Medical Practice Representation
• Medicare, Medicaid, and Other Commercial Payor Audits & Appeals
• Mergers & Acquisitions
• Out-of-Network Provider Issues
• Pain Management Compliance
• Palliative Care, Hospice Care and Home Care
• Physician Dispensing
• Private Equity Investing
• Professional Board Actions
• Regenerative Medicine, Anti-Aging and Wellness
• Telemedicine & Telehealth
• Value Based Care
• Government Investigations, Litigation & White-Collar Defense
• 340B Covered Entity and Contract Pharmacy Regulatory and Contract Support
• Antitrust Tools Available to Combat PBM Abuse of Pharmacies
• Board of Pharmacy Investigations
• Defending Pharmacies in PBM Audits
• Federal & State Fraud and Abuse Counseling
• MAC Pricing & Appeals
• Medicare Advantage Risk Adjustment Litigation
• Medicare Audit Appeals
• Payor Network Access and Defense of Network Terminations
• PBM Qui Tam Lawsuits
• Pharmacy Transactions
• Plan Sponsor PBM Contract Services
• Private Equity Investing in Specialty Pharmacy & Pharmaceutical Companies
• Review of Promotional and Advertising Materials
• Risk Assessment Mitigation Strategy
• Telehealth & Telemedicine
• Ambulatory Care Facilities/Ambulatory Surgery Centers (ASCs)
• Behavioral Health Practitioners
• Clinically Integrated Networks (“CINs”)
• Dental Practices
• Dispensing Physician Practices and Dispensing Physicians
• Hospitals and Healthcare Systems
• Laboratories
• Management Services Organizations (MSOs)
• Medical Spas
• Physicians and Medical Practices of all Specialties
• Skilled Nursing Facilities and Long-Term Care
• Start-Up Healthcare and Life Sciences Companies
• Value Based Care Organizations: ACOs, IPAs and CINs
• Biotechnology Companies
• Chain Pharmacies
• Community, Retail Pharmacies
• Compounding Pharmacies (503A)
• Fertility Pharmacies
• Home Infusion Providers
• Hospitals and Health Systems
• Integrated Delivery Network
• Long-Term Care Pharmacies
• Outsourcing Facilities (503B)
• Pharmaceutical Manufacturers
• Pharmaceutical Wholesalers
• Plan Sponsors and Plans
• Specialty Pharmacies
• State & National Pharmacy Association
• Supermarket Pharmacies
• Veterinary Compounders
• Articles & Publications
• Events & Presentations
• On-Demand Webinars
• Download Tools
• Recent Results

UnitedHealth Group Inc to buy Catamaran Corp for $12.8 billion to boost pharmacy services

UnitedHealth Group Inc, America's largest health insurer, is staking a bigger claim in pharmacy benefits management with a plan to buy Catamaran Corp., its biggest purchase ever

You can save this article by registering for free here . Or sign-in if you have an account.

Article content

UnitedHealth Group Inc.’s OptumRx agreed to buy Catamaran Corp., a provider of pharmacy benefit management services, for about US$12.8 billion in the company’s largest purchase ever, to add clients and improve its technology.

UnitedHealth will pay US$61.50 a share in cash, financing the acquisition with existing cash and new debt, the companies said in a statement. That’s 27% more than Schaumburg, Illinois-based Catamaran’s closing share price of US$48.32 on Friday.

UnitedHealth Group Inc to buy Catamaran Corp for $12.8 billion to boost pharmacy services Back to video

Subscribe now to read the latest news in your city and across Canada.

• Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
• Daily content from Financial Times, the world's leading global business publication.
• Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
• National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
• Daily puzzles, including the New York Times Crossword.
• Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.

Create an account or sign in to continue with your reading experience.

• Access articles from across Canada with one account.
• Share your thoughts and join the conversation in the comments.
• Enjoy additional articles per month.
• Get email updates from your favourite authors.

Sign In or Create an Account

“The combination diversifies OptumRx’s customer and business mix, while accelerating its technology leadership and flexible service offerings,” the companies said. Catamaran adds an “industry-leading technology platform” to OptumRx’s capabilities in data and analytics, they said.

OptumRx and Catamaran offer specialty pharmacy services, an industry with about US$100 billion in annual revenue that may quadruple by 2020, the companies said. Catamaran manages more than 400 million prescriptions a year for 35 million members, while OptumRx manages prescription drug benefits for commercial and governmental health plans and works through a network of about 66,000 community pharmacies and mail-order pharmacies.

“The combination of the two companies will create a unique offering in the industry unparalleled by current participants,” Larry Renfro, CEO of OptumRx, said in the statement.

Mark Thierer, Catamaran’s chairman and chief executive officer, will become CEO of OptumRx, and Timothy Wicks, the current CEO, will become president, according to the statement. The purchase is expected to be completed in the fourth quarter of 2015, and will add about 30 U.S. cents to UnitedHealth’s earnings per share in 2016, the companies said. Bloomberg.com

Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.

David Rosenberg: Canada is in crisis, but maybe not for much longer

Bank of canada on 'straightline path' toward two more cuts: scotiabank's holt, air canada prepares shutdown ahead of looming strike deadline, a new government is needed to unwind nine years of liberal tax mistakes, posthaste: how higher savings rate might not save canadians from the mortgage cliff.

This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here . By continuing to use our site, you agree to our Terms of Service and Privacy Policy .

You've reached the 20 article limit.

You can manage saved articles in your account.

and save up to 100 articles!

Looks like you've reached your saved article limit!

You can manage your saved articles in your account and clicking the X located at the bottom right of the article.

M&A Deal Summary

Optumrx acquires catamaran, on march 30, 2015, optumrx acquired healthcare services company catamaran for 12.8b usd, acquisition highlights.

• This is OptumRx’s 1st transaction in the Healthcare Services sector.
• This is OptumRx’s largest (disclosed) transaction.
• This is OptumRx’s 1st transaction in the United States.
• This is OptumRx’s 1st transaction in Illinois.

Search 197,707 Deals Now

• Buyer Type (PE or Strategic)
• Deal Size ($10M to $10B+)
• Sector (60 Sectors)

Try For Free 7-Day Free Trial

DESCRIPTION

OptumRx specializes in the delivery, clinical management and affordability of prescription medications and consumer health products.

FOLLOWING DEAL

• Mergr for Salesforce
• Mergr Data Direct
• Mergr M&A Archive
• Pitchbook Alternative